Compare GSK plc (GSK) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Snowflake Inc — how do they compare? GSK plc trades at $52.66 (market cap $101.34B), while Snowflake Inc trades at $273.86 (market cap $94.23B). The key difference: GSK plc and Snowflake Inc are close in size by market cap, and GSK plc pays a 3.49% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals.
| GSK | SNOW | |
|---|---|---|
Market Cap | $101.34B | $94.23B |
Sector | Health | Technology |
52-Week High | $61.18 | $280.16 |
52-Week Low | $36.20 | $121.11 |
Enterprise Value | $121.95B | $94.05B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Snowflake (SNOW) trades at $275.94, up 2.71% with strong technical momentum as moving averages signal bullish alignment. The company demonstrates robust revenue growth reaching $3.63 billion in 2025, though remains unprofitable with a -23.79% net margin. Recent earnings beats and accelerating AI Data Cloud adoption fuel optimism, while analyst consensus remains strongly bullish with an $297.35 price target representing 8% upside potential from current levels.
Snowflake's outlook balances rapid revenue expansion against persistent profitability challenges. The $80 billion data market opportunity and AI platform traction offer substantial growth potential, but premium valuation (P/S 18.4) and intense cloud competition present risks. Institutional sentiment remains positive with 81% buy ratings, though investors should monitor margin improvement and competitive positioning in the evolving enterprise AI landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
